Long persistence of TNF-α antagonist induced autoantibodies under subsequent treatment with Ustekinumab but no adverse effects: a case study of 14 psoriasis patients

Abstract

Induction of antinuclear antibodies (ANA) is a well-documented side effect of treatment with the TNF-α antagonists Infliximab, Adalimumab, and Etanercept. In this context, occasional organ-specific and systemic autoimmune phenomena, and an association of autoantibodies with treatment response and anti-drug antibody formation were reported. In genuine autoimmune disease, the detection of autoantibodies can predate clinical manifestations by almost 6 years. However, little is known about the post-treatment dynamics of TNF-antagonist induced ANA, and, in particular, on their effects on the response to, and their dynamics under subsequent biologic treatment.

This article is protected by copyright. All rights reserved.

http://ift.tt/2rBEMvU